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Summary.-The immunoprophylactic effects of the methanol extraction residue
(MER) of BCG were investigated in Strain 2 guinea-pigs injected with cells of the
transplantable, diethylnitrosamine-induced, Line 10 hepatocarcinoma. Pretreat-
ment with MER at times ranging from 18 to 182 days prior to tumour implantation
protected approximately 40o% of guinea-pigs from progressive neoplastic disease.
In addition, MER-treated animals developed specific cell-mediated anti-tumour
immunity both more rapidly and at higher levels than did non-MER-treated tumour-
bearing controls. It was not possible, however, to prognosticate from the results of
such laboratory studies to the outcome of immunoprophylaxis.
Both intact Bacillus Calmette-Guerin
(BCG) and the methanol extraction residue
(MER) (Weiss and Wells, 1960) of BCG
have had extensive application in recent
years in tumour immunoprophylaxis and
immunotherapy (Mathe, Pouillart and
Lapeyraque, 1969; Bast et al., 1974;
Haran-Ghera and Weiss, 1973; Hopper,
Pimm and Baldwin, 1975). Treatment
with MER non-specifically stimulates both
the humoral and cellular immune systems
(Ben-Efraim, Constantini-Sourojon and
Weiss, 1973; Kuperman et al., 1972), and
has been shown to be successful in tumour
immunotherapy in a number of animal
models. This communication discusses
mechanisms whereby pretreatment of
certain groups of animals with MER can
afford protection against the growth of
subsequently implanted transplantable
tumour cells.
The model system we have been
studying is the inbred Strain 2 guinea-pig
transplantable Line 10 hepatocarcinoma
(Zbar et al., 1969). This tumour was
originally induced atthe National Institute
of Health (NIH), Bethesda, Md., by the
carcinogen diethylnitrosamine, and has
been shown to be susceptible to immuno-
prophylaxis when Strain 2 animals of
breeding colonies other than that of the
NIH are employed (Minden, Wainberg and
Weiss, 1974b; Zbar et al., 1976). Previous
studies from our laboratory with Strain 2
guinea-pigs obtained from the Weizmann
Institute of Science (WI), Rehovot, Israel,
indicated that pretreatment with either
MER or another sub-cellular fraction of
BCG designated BCG-SS (Minden and
Farr, 1969), at times as much as 58 days
prior to tumour cellimplantation, protect-
ed over 400o of guinea-pigs injected with
tumour cells from subsequent progressive
disease (Minden et al., 1974b). We now
report that animals which receive MER
immunoprophylactically develop anti-
tumour immunity both more rapidly and
at higher levels than do non-MER-treated
tumour-bearing controls. In addition,
the MER tumour-preventive effect appears
to be sensitive to experimental manipu-
lation, and may be abrogated by the use
of several tumour implantation sites.
MATERIALS AND METHODS
Animals and tumour cells.-Sewall-Wright
inbred Strain 2 guinea-pigs were obtained
from the breeding colonies of the WeizmannIMMUNOPROPHYLAXIS BY BCG EXTRACT
Institute of Science, Rehovot, Israel. The
ascites form of the Line 10 hepatocarcinoma
was kindly provided in the fourteenth trans-
plant generation by Dr B. Zbar, National
Cancer Institute, Bethesda, Md., and main-
tained by syngeneic i.p. passage in Strain 2
animals. Tumour-cell suspensions for intra-
dermal (i.d.) challenge were prepared im-
mediately before use, as described previously
(Minden et al., 1974b) and adjusted to a
concentration of 107 hepatoma cells/ml of
Hanks' balanced salt solution (BSS). Ani-
mals were injected i.d. into the right flank
with 106 tumour cells in01 ml BSS. Tumour
growth was measured across 2 perpendicu-
lar diameters by means ofa pair ofcalipers, at
least twice wveekly.
Methanol extraction residue (MIER). The
MER fraction of phenol-killed BCG (Phipps
strain) w%as used in these experiments. MER
has been previously show,n to possess non-
specific humoral and cellular immunological
adjuvant properties in a variety of animals
(Ben-Efraiin et al., 1973; Kuperman et al.,
1972), and has recently been used success-
fully in tumour immunotherapy in both
animals and man (Hopper et al., 1975; Cohen
et al., 1975; Weiss et al., 1975). MER was a
gift from the division of Cancer Treatment,
National Cancer Institute, Bethesda, Md.
Strain 2 male and female guinea-pigs were
injected i.d. with MER (0 5-1 0 mg in 041 ml
isotonic saline) into the left flank at times up
to 182 days prior to the contralateral inocu-
lation of tumour cells. In some cases,
animals Awere treated both prophylactically
as described and therapeutically by the
injection of MER (0.5 mg) into developing
tumour nodules 7 days after tumour implant-
ation. Non-MER-treated tumour-injected
guinea-pigs served as controls.
Soluble tissue extracts and delayed cutaneous
hypersensitivity (DCH)studies. Solubletissue
components wAere prepared by 3M KCI
extraction from both ascites-grown Line 1]0
tumour cells (SA-10) and from perfused
normal adult liver tissue (SA-N) by a modi-
fication of the procedure of Meltzer et al.
(1971) as previously described (Minden et al.,
1974a), and stored at -20°C until use. Pro-
tein concentrations were determined by the
method of Lowry et al. (1951). These
extracts wNere used in DCH studies (10 ,ug
protein per test) in both MER-treated and
control tumour-cell-injected guinea-pigs.
Skin testing wvas also carried out with
purified protein derivative (PPD) of llMyco-
bacterium tuberculosis (2,tg per test), kindly
supplied by the Ministry of Agriculture,
Weybridge, England. All test inocula were
administered in 041 ml of isotonic saline.
Areas ofinduration were measured after 24 h.
Migration inhibition of peritoneal exudate
cells.-Peritoneal exudate cells (largely mac-
rophages) were harvested from MER-immune
or normal animals 3 days after i.p. injection of
30 ml of a sterile 2.5% solution of sodium
caseinate in isotonic saline. The cells were
washed 3 times by centrifugation at 250 g for
10 min at room temperature in medium 199
(supplemented with 10% inactivated calf
serum, 100 u/ml of penicillin, 100 Hg/ml of
streptomycin, and 15-25 ml/l of5oo NaHCO3)
and resuspended to a concentration of5 x 107
cells/ml in capillary tubes plugged at one end
wvith " Seal-Ease " clay (Clay Adams, Parsip-
pany, New-Jersey). The capillaries werethen
centrifuged at 150 g for 4 min, cut at the cell-
fluid interface, and affixed with silicone wax
in Sykes-Moore tissue culture chambers
(Bloom and Bennett, 1971). The chambers
were filled with tissue culture medium, in the
presence or absence of various concentrations
of antigen (i.e. 100l,g SA-10; l00 g SA-N;
or 40 Hg PPD, per chamber), and incubated
at 37TC for 24 h. After incubation, areas
covered by migrating cells were magnified on
to paper by projection microscopy and
measured by planimetry (Jokipii and Jokipii,
1974). All migration inhibition studies were
performed with4replicatesamples. Antigen-
incubated cultures showing levels of cellular
migration less than 80% of those seen in
control cultures were considered to have
produced migration inhibition factor (MIF).
Lymphocyte stimtulation.-Blood from
Strain 2 guinea-pigs was drawn into heparin
by cardiac puncture, and the mononuclear
fraction purified by Ficoll-Isopaque gradient
centrifugation (Boyum, 1968). This fraction,
which consisted largely of lymphocytes, was
collected by aspiration, washed twice by
centrifugation for 15 min at 500 g in BSS,
and the cells resuspended in bicarbonate-
buffered medium RPMI (supplemented with
10% foetal calf serum, 100 u/ml penicillin,
100,tg/ml streptomycin) to a final concen-
tration of 106/ml. Cultures containing 1 ml
of cell suspension in (17 x 100) mm tubes
were incubated in the presence or absence of
various test antigens (i.e. 100 ,ug SA-N;
100 utg SA-10) for 72 h at 37°C. Tritiated
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thymidine (1 ,uCi/tube; New England Nuclear,
Boston, Mass.) was added to the culture tubes
forthefinal 16hofincubation, followingwhich
the samples were processed bytrichloroacetic
acid precipitation on to filter pads and the
amount of incorporated radioactivity deter-
mined.
RESULTS
1. Effect of pretreatment of guinea-pigs
with MER on subsequent tumour develop-
ment
A previous study showed that pre-
treatment of guinea-pigs with MER as
much as 58 days prior to tumour implanta-
tion protected a significant proportion of
animals from Line 10 metastatic disease.
We now report that this protective effect
is observed even when tumour cell injec-
tion is preceded by MER inoculation by
as much as 6 months.
Strain 2 guinea-pigs were treated with
MER (0 5-1 0 mg) in each of 4 separate
experiments, at times ranging from 18 to
182 days prior to subsequent distal i.d.
implantation of 106 Line 10 tumour cells.
In all, 14 of 33 MER-treated animals
survived tumour challenge, as opposed to
none of 16 tumour-injected controls (Table
I) (P < 0.01; X2 test).
A graphic representation from one
such experiment ofline 10tumour develop-
ment in both MER-pretreated and non-
treated guinea-pigs is shown in the Fig.
All tumour-cell-injected animals developed
growing tumour nodules by 7 days after
line 10 challenge. Growthofthesenodules
was arrested in numerous MER-pretreated
animals at about this time, but not in the
controls, in which progressive tumour
enlargement, accompanied by metastasis
to the regional lymph nodes and death,
invariablyoccurred. Insome cases, MER-
treated guinea-pigs whose primary tumour
nodules had ceased to enlarge developed
sudden lymph node metastases and died
as well. All control guinea-pigs suc-
cumbed between 60 and 80 days following
tumour inoculation.
The fact that pretreatment with MER
protected a substantial percentage of
guinea-pigs against subsequent distal
implantation of tumour cells suggested
that the effects of MER were mediated
systemically. Studies designed to shed
lightonthisphenomenon, however, yielded
a confusing picture. When the tumour
cell inoculum was divided into equal doses
of 5 x 105 cells, each administered into
the opposite flanks of 16 animals treated
30 days previously withMER (0 5-1 0 mg),
no protection was observed (Table II).
By contrast, 7 of 16 MER-pretreated
guinea-pigs injected with 106 tumour cells
at one site only survived (P < 0-01; x2
test). These findings imply that the
burden of handling 2 simultaneously
developing tumour nodules is too great for
the defence mechanisms of these animals,
even when pretreated with MER, and
point to the complexity of the circum-
TABLE I. Prophylactic Effect of MER on Line 10 Tumour Development
Dose of MER
Expt. employed
(mg)
1 0 5
1.0
2 0-5
3 0*5
1*0
4 1.0
Days prior to
tumour implantation
182
182
45
30
30
18
No. No.
of animals of survivors
3
3
3
6
63
6
6
5
9
5
2
0
4
0
2
3
0
2
0
Average
clay of death of
non-survivors*
71
70
66
68
61
69
67
64
67
64
* Days following tumour cell implantation.
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stances in which tumour regression may
occur.
2. Delayed cutaneous hypersensitivity
studies in MER-pretreated animals
In order to determine whether the
observed tumour prophylaxis effect of
MER could be attributed, in part at least,
to a stimulation of specific anti-tumour
immunity, 3 different techniques for the
detection of cellular immune response
were employed: delayed cutaneous hyper-
sensitivity (DCH), macrophage migration
inhibition and lymphocyte blastogenesis.
Seven of the animals of Table II which
were pretreated with MER, as well as 3
untreated tumour-injected controls (from
the same experiment), were skin-tested at
various times following tumour cell inocu-
lation with PPD (2 ,g), SA-N (10 ,ug)
and SA-10 (10 leg). The results (Table
III) revealed PPD skin sensitivity only
in those animals which received MER.
In addition, MER-injected guinea-pigs
were observed to develop DCH to SA-10
TABLE II. Prophylactic Effect of MER
on the Growth of Line 10 Hepatoma
Implants
Number of ttumour
Pretreatment of cells iiijecte(d inlto:
guinea-pigs at
-30 days Left flanik Right flank
AIER,0 5mg 5x 105 5x105
AIER,0 5 mg 10t
MER, 1-0 mg 5x 105 5x 105
MER, 1l0 mg 106
5x 105 5x 105
106
No. of
survi-vors/
Total
numbers
0/8
:38
0/S
4/8
0/8
0/8
by only 14 days after tumour cell implant-
ation. In non-MER-injected tumour-
bearing controls, DCH to SA-10 was
not observed until after 21 days. More-
over, skin reactions to SA-10 were
qualitatively more intense in the MER-
injected guinea-pigs. No differences were
observed, however, with regard to immune
responsiveness, at the time tested, between
those animals which received MER and
survived tumour challenge and those
animals which received MER and eventu-M. A. WAINBERG, V. DEUTSCH AND D. W. WEISS
TABLE III. Effect ofPretreatment with MER on Skin Test Sensitivity to PPD and
Soluble Tumour Antigen
Treatment Day of
Animal mg AIER (leatht
1 ~~~~58
1) 62
3 - 64
4 0.5* 56
5 O a05 61
6 1.0 64
7 1-0 59
8 0 5
9 1-0
10 1-0
Skin test Ag
PPD (2 jig) SA-N (10 jig)
Day 0 Day 14 Day 21 Day 0 Day 14 Day 21
0 t
0
0
6 x 7
9x 10
7 x 5
12 x 10
14x 12
9 x 10
8 x 8
0
0
0
lOx 11
14x 15
9 x 9
9 x 9
15 x 14
12 x 14
17 x 16
0
0
8 x 8
lox 11
11 x 12
14x 16
15x 17
18 x 15
17 x 15
0
0
0
0
3 x 4
0
0
0
3x4
0
4 x 5
0
0
4x4
4 x 4
0
0
0
0
0
0
0
0
0
5 x 4
0
0
0
0
SA-10 (10 jig)
Day 0 Day 14 Day 21
0
0
0
0
0
0
0
0
0
0
0
0
0
7 x 6
6 x5
7 x 8
0
lOx Il
lI x 9
9x 10
l 0 x 8
9x 10
8 x 9
11 x 13
9x 12
14 x 12
11 x 14
15x 12
13 x 14
17x 15
* MIER iinjected into one flank 30 davs prior to the contralateral inoculation of 106 tumour cells.
t Size of induration (mm).
I Days following tumour cell implantatioll.
ally succumbed. DCH reactivity against a second intralesional dose (0.5 mg) 7 days
SA-N was not detected. after tumour implantation. The peri-
toneal cavities of these animals were 3. Mlacrophage migration inhibition studies stimulated at various times, as described
In these studies, treated animals above, and peritoneal exudate (PE) cells
received MER on 2 separate occasions: harvested between 3 and 41 days after
both 18 days (1 mg) prior to the contra- tumour injection. PE cells were exposed
lateral inoculation of 106 tumour cells and over 24 h to either PPD (40 ,ug) or SA-lO
nrABLE IV. Effect ofTreatment with MER on MIF Production in Response to
PPD and Soluble Tumour Antigen
Treatment Day of deatht.
56
59
53
TAIER § 56
AIER 53
MER 57
MER 56
MER 56
MER 61
MER 46
MER 71
MER 66
MER 70
MER 48
MER 48
MER 48
MER
MER
MER
0/ PE cell migration*
PPD (40 jig) SA-10 (100 lig)
loot 105
83 82
103 100
88 93
67 78
70 79
73 85
72 104
71 77
73 82
68 102
71 66
47 99
48 74
72 64
144 108
87 93
65 79
30 38
69 105
Day of assayl
17
32
25
41
:
3
3
10
10
10
17
17
25
25
32
41
41
17
32
32
* ,, of control cultures inicubated in absence of stimulant.
t Mean of 4 replicate samples.
+ Following challenge wxith 106 tumour cells.
§ MER injectect into one flank (1-0 mg) 18 days prior to the contralateral inocuilationi of 106 tumour
cells and intralesionally (0* 5 mg) 7 days after tumour implantation.
Anim-ial
3
4
5
6
7
8
9
10
I 1
12
13
14
15
16
17
18
19
20
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(100 ,tg), and areas of cellular migration
calculated.
The animals of this experiment were
not sacrificed at the time of PE cell
harvest, but followed for immunothera-
peutic response to MER. The results
(Table IV) indicated that 14 of 16 animals
which had received MER, as opposed to
none of 4 tumour-injected controls, showed
immune responsiveness (i.e. > 20% in-
hibition of migration) against PPD (40 ,ag)
(P < 0-001; X2 test). Reactivity to SA-
10 (100,g) was seen with 8 of 16 MER-
treated, tumour-injected guinea-pigs and
none of 4 Line-10-bearing controls (P
< 0.01; x2 test). Moreover, borderline
reactivity against SA-10 was detected in
the case of 2 animals which had been
inoculated only 3 days previously with
tumour cells, a phenomenon possibly
attributable to observed antigenic sharing
between the Line 10 tumour and BCG
(Minden et al., 1974a). Only 3 of the 16
MER-treated animals of this experiment
survived tumour challenge. The reasons
for this relatively low survival rate are
uncertain, but may be related to the fact
that these animals had been traumatized
both by stimulation and by the tapping of
the peritoneal cavity for PE cells. Along
these lines, it is worth noting that most of
the animals of this experiment which
succumbed, including non-MER-injected
controls, died earlier (average day of
death; 56 days) than did guinea-pigs
which had not been subjected to experi-
mental manipulation in the manner de-
scribed (Table I, average day of death;
66 days).
4. Lymphocyte stimulation
The ability of SA-N and SA-IO to
stimulate the peripheral lymphocytes of
the MER-pretreated, tumour-injected
guinea-pigs and tumour-bearing controlsof
Table I, Experiment I, was assessed by
measuringincorporation of[3H]thvmidine,
both in the presence and absence of
stimulant. The results (Table V) showed
specific reactivity to SA-10 to be present
in each of 9 animals which had been
inoculated 21 days previously with tumour
cells. Levels of anti-SA-10 response in
MER-pre-treated guinea-pigs were gener-
ally higher than those of controls, while
reactivity against SA-N was not detected.
As reported for the results ofDCH studies,
however, no differences were observed
between MER-pretreated animals which
survived tumour challenge and those
which did not. These results supple-
ment similar observations on levels of
anti-tumour immunity in Line 10 tumour-
bearing guinea-pigs which had been
treated immunotherapeutically with living
BCG (Littman et al., 1973).
DISCUSSION
The results reported here confirm
previous observations from our labora-
tories that MER is an effective immuno-
prophylactic agent against the transplant-
able Line 10 hepatocarcinoma in Strain 2
guinea-pigs obtained from the breeding
colonies of the Weizmann Institute of
Science, Rehovot, Israel (Minden et al.,
1,974b). Moreover, MER administration
may precede tumour cell implantation by
as much as 6 months and still be effective.
This protective effect, however, is
sensitive to experimental manipulation,
and may be abrogated by the use of
several tumour implantation sites. This
suggests that the defence mechanisms of
these animals, even following pretreat-
ment with MER, may be unable to cope
with the presence of two simultaneously
developing tumour nodules, and points to
the complexity of the circumstances in
which tumour regression may occur.
Along these same lines, it should be noted
that MER pretreatment is apparently
successful in preventing a proportion of
Strain 2 guinea-pigs bred at either the
Weizmann Institute of Science or the
National Jewish Hospital, Denver, Colo.,
from developing cancer, but is without
effect when animals raised at the National
Institutes of Health (NIH) (Zbar et al.,
1976) are employed. Similarly, we have
shown in immunotherapy protocols that
inoculation of MER (0.5-1.0 mg) into
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developing tumour nodules, 7 days after
implantation of 106 Line 10 cells, is more
effective inguinea-pigs ofeitherWeizmann
Institute or Denver than NIH origin
(Wainberg, Margolese and Weiss, 1976).
This raises the question whether the
various substrains of guinea-pigs used in
this research are isogenic with respect to
one another, and more importantly,
whether they may differ from the trans-
plantable Line 10 hepatoma in terms of
histocompatibility antigen make-up. In-
deed, should histocompatibility differences
exist, then at least part of the tumour
rejection phenomenon which both we
(Minden, et al., 1974b; Wainberg et al.,
1976) and others (Zbar and Tanaka, 1971;
Zbar, Bernstein and Rapp, 1971) have
observed may be due to homograft rather
than tumour immunity. If this is the
case, however, it is nonetheless obvious
that the histocompatibility differences
must be minor, since tumour inoculation
in the absence of immunoprophylaxis or
immunotherapy has been invariably fatal
for the animals we have studied. For
this reason, it is fair to speak of anti-
tumour immunity in this system. These
difficulties may be intrinsic to many or all
tumour transplantation models.
Our results also indicate that animals
pretreated with MER generally develop
cellular anti-tumour immunity both more
rapidly and at higher levels than do non-
MER-treated, tumour-bearing controls,
as measured by each of 3 different pro-
cedures. This applies to all animals
which receive MER immunoprophylaxis,
regardless of whether they eventually
survive tumour challenge or succumb to
progressive disease. Thus, we have not
been able to prognosticate the outcome of
MER pretreatment by our various in
vitro and in vivo testing procedures.
Similar findings, were previously reported
for this model, based on immunotherapy
experiments usinglive BCG (Littman etal.,
1973). These data may suggest, there-
fore, that the T lymphoid cell population
which we have been monitoring by these
techniques is not of foremost importance
as far as tumour rejection is concerned.
Others (Evans and Alexander, 1972;
Droller and Remington, 1975; Norbury
and Fidler, 1975) have suggested that the
macrophage is the most likely candidate
for the role of critical effector cell in
tumour immunology.
Nevertheless, the heightened levels of
cell-mediated anti-tumour immunity
which we have observed following MER
pretreatment maybe related, perhaps in a
cooperative way, to ultimate survival.
Earlier studies with other models, while
showing that BCG can exert a tumour
immunoprophylactic effect, did not pro-
vide ancillary data as to whether or not
overall stimulation of specific anti-tumour
immunity also occurred (Old, Clarke and
Benacerraf, 1959; Lemonde et al., 1971;
Keller and Hess, 1972). Our findings in-
dicate that such stimulation does take
place.
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